Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Hodgkin Disease 36 Lymphoma 34 Lymphoma, Non-Hodgkin 24 Lymphoma, Large B-Cell, Diffuse 24 Lymphoma, Follicular 18 Lymphoma, B-Cell 16 Recurrence 15 Melanoma 14 Neoplasms 12 Mycosis Fungoides 9 Lymphoma, T-Cell 9 Breast Neoplasms 9 Leukemia, Lymphocytic, Chronic, B-Cell 8 Carcinoma, Non-Small-Cell Lung 8 Squamous Cell Carcinoma of Head and Neck 7 Lymphoma, T-Cell, Cutaneous 7 Lymphoma, B-Cell, Marginal Zone 7 Head and Neck Neoplasms 7 Sezary Syndrome 6 Pancreatic Neoplasms 6 Ovarian Neoplasms 6 Lymphoma, Mantle-Cell 6 Lung Neoplasms 6 Carcinoma, Renal Cell 6 Parkinson Disease 4, Autosomal Dominant Lewy Body 5 Neoplasm Metastasis 5 Lymphoma, T-Cell, Peripheral 5 Waldenstrom Macroglobulinemia 4 Uterine Cervical Neoplasms 4 Urinary Bladder Neoplasms 4

Interventions

pembrolizumab 1 dinaciclib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

rrCLL × pembrolizumab × Lymphoid × Clear all

NCT02684617 2021-03-01

KEYNOTE-155

Merck Sharp & Dohme LLC

Phase 1 Terminated

75 enrolled 17 charts

rrCLL

Data powered by HemOnc (CC BY 4.0) Colophon ⚡